Johnson & Johnson sees big things ahead for California's NeuroVision, so it's expanding its partnership with the company. The move gives NeuroVision a boost as it looks to grab a bigger piece of the market for its Alzheimer's eye-imaging diagnostic.
Rodin Therapeutics recruited Biogen to help advance its novel approach to Alzheimer's disease in a pairing that could end with the Atlas Venture company getting bought for $485 million.
Singapore-based TauRx is expected to complete global Phase III trials this year for its Alzheimer's candidate, tau aggregation inhibitor LMTX, that will either start a new chapter in treatment or join a long list of flops.
Some of the top companies in Big Pharma have contributed to a $100 million venture fund that will be invested in R&D aimed at finding new therapies for Alzheimer's.
Advera Health Analytics: Novartis, Allergan Alzheimer's meds linked to abnormal behavior, blood pressure side effects
Healthcare informatics company Advera Health Analytics delved into FDA postmarketing safety reports and compiled data on Alzheimer's drugs. The firm found that Novartis' Exelon patch, Allergan's Namenda and Eisai's Aricept showed more reports of serious side effects than other drugs, with safety issues ranging from convulsions and gastrointestinal hemorrhage to respiratory failure and sudden death.
Tech titans like Google, Samsung and Apple have clear med tech ambitions. Now a food giant is trying to grab a slice of the pie. The Nestlé Institute of Health Sciences SA seeks to deploy its proprietary diagnostic technology platform to develop an assay for the early detection of Alzheimer's.
By studying a group of outliers in a Colombian family known for the prevalence of early-onset Alzheimer's, investigators at UC Santa Barbara believe they may have fingered a new drug target that could delay the disease by a decade or more.
Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar.
As scientists zero in on quick, inexpensive ways to screen for Alzheimer's, a New York startup is developing a video game-like tool for catching early signs of the disease.
Shares of Vitae Pharmaceuticals dropped 5% this morning after the biotech reported that Boehringer Ingelheim had decided to dump its collaboration on a new BACE program for Alzheimer's.